Eisai Co., Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (4)

Latest Posts

About This Stock More About This Stock
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Article By: ChinaBio® Today
Sunday, February 11, 2024 12:40 PM EDT
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
In this article: BAYRY, TRIB, IMAB, IVBXF, ESAIY
Read
Current Analysis: Eisai Co Ltd (ESAIY)
Article By: Fredrik Arnold
Sunday, July 16, 2023 10:28 PM EDT
Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.
In this article: ESALF, ESAIY
Read
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Article By: ChinaBio® Today
Saturday, May 13, 2023 3:00 PM EDT
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr. Reddy’s Labs in a deal worth up to $728 million.
In this article: ESAIY Also: RDY, RHHBY, ACOR, LIAN, EQRX, IVBXF, CSPHF
Read

Latest Tweets for $ESAIY

No tweets yet!

PARTNER HEADLINES